Hansa Biopharma: Improved sales prospects - Redeye

Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and supporting pipeline progress over the next 12 months. Many countries supported the European launch, and the Eurotransplant program was initiated. Our Base Case is SEK110 (100) with a Bull Case of SEK210 (210) and a Bear Case of SEK15 (15).

Länk till analysen i sin helhet: https://www.redeye.se/research/974575/hansa-biopharma-improved-sales-prospects?utm_source=finwire&utm_medium=RSS